Pharmacologic Weight Loss (Saxenda, Wegovy) — Coverage Criteria
Customize your policy alerts
Sign up for all Neighborhood Health Plan of Rhode Island policy alerts
Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Defines documentation, eligibility, prior authorization, continuation, dosage limits, and FDA dosing recommendations for liraglutide (Saxenda) and semaglutide (Wegovy) for commercial members of Neighborhood Health Plan of Rhode Island.
No material clinical or coverage changes in this revision.
Coverage Criteria for Saxenda and Wegovy
Initial Therapy
Covered when ALL of the following are met:
Authorization may be granted for 6 months.
Continuation Therapy
Covered when ALL of the following are met:
Authorization may be granted for 6 months.
Use of these agents in combination with another GLP-1 receptor agonist is not permitted. Requests for initial or continuation therapy must document that the patient is not using combination therapy with any other GLP-1 receptor agonist to meet coverage criteria.
If the patient fails to achieve the required weight-loss response during the specified trial period, continuation of therapy is contingent on documentation of active participation in a comprehensive weight‑loss program. For adults, continuation criteria generally require ≥5% reduction from baseline body weight after the mandated trial (with completion of the specified weeks on therapy and being on the FDA‑recommended maintenance dose); if no further weight loss and BMI remains ≥25, the provider must submit documentation showing ongoing participation in a comprehensive program (this allowance is limited to one approval). For pediatric Saxenda (ages 12–17) a 1% BMI reduction from baseline without further improvement similarly requires documentation of continued program participation for consideration of a single approval.
Formulations, Quantity Limits, and Eligibility Metrics
| Saxenda 1.8 mg/3 mL | Quantity limit: 5 pens per 30 days |
| Wegovy 0.25 mg, 1 mg, 2.4 mg | Quantity limits and pen supply: 4 pens per 28 days (formulations listed) |
| Wegovy 0.25 mg, 1.7 mg, 2.4 mg, 5 mg, 1 mg | Formulations listed in source; quantity limits: 4 pens per 28 days |
Prior Authorization and Documentation Requirements
Prior authorization period — up to 6 months
Prior authorization may be approved for a maximum of 6 months when all documented clinical criteria and program participation requirements are met.
Require 6 months of documented comprehensive weight management
The member must have documentation of current, active participation in a comprehensive weight management program that includes behavioral modification, reduced calorie diet, and increased physical activity with at least monthly follow-up for a minimum of 6 months prior to drug therapy.
- Program components: behavioral modification, nutrition, and physical activity
- Minimum frequency: monthly follow-up
- Minimum duration: at least 6 months
Submit baseline weight, BMI, and program participation notes
For initial prior authorization requests submit baseline weight and BMI plus clinical notes documenting current participation in a comprehensive weight management program with monthly follow-up for at least the past 6 months; for continuation requests submit baseline and current weight and BMI and clinical notes documenting tolerability and continued diet and activity.
- Initial requests: baseline weight, BMI, and clinical notes showing active participation in comprehensive program with monthly follow-up for ≥6 months
- Continuation requests: baseline and current weight and BMI, clinical notes documenting tolerability and continued reduced calorie diet and increased physical activity
Missing documentation may cause denial or delay
Failure to submit the required documentation (baseline weight, BMI, and clinical notes documenting participation in a comprehensive weight management program) may result in delay or denial of the authorization request.
Background and Scope
This policy addresses pharmacologic management of obesity with GLP‑1 receptor agonists (liraglutide [Saxenda] and semaglutide [Wegovy]). Coverage is limited to patients meeting BMI‑based thresholds (adults with BMI ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity‑related comorbidity; pediatric patients aged ≥12 years meeting age‑ and sex‑standardized obesity criteria) and who document active participation in a comprehensive weight management program emphasizing behavioral modification, reduced calorie diet, and increased physical activity. Continued coverage requires demonstrated tolerability, specified time on therapy at the FDA‑recommended maintenance dose, and achievement of the policy’s weight‑loss response thresholds (e.g., ≥5% weight loss for most adults or pediatric Saxenda criteria), with prior authorization periods granted for up to 6 months when criteria are met.
Pediatric BMI and Obesity Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.